Wird geladen...
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Drug repositioning is an emerging approach to developing novel cancer treatments. Vorinostat is a histone deacetylase inhibitor approved for cancer treatment, but it could attenuate its anticancer activity by activating the mTOR pathway. The HMG‐CoA reductase inhibitor fluvastatin reportedly activat...
Gespeichert in:
| Veröffentlicht in: | Cancer Sci |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6942444/ https://ncbi.nlm.nih.gov/pubmed/31675763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14225 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|